These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring

Psychedelic medicines are rapidly gaining legitimacy on several fronts. As a psychedelic therapy developer, Compass Pathways (CMPS 1.02%) is on the cutting edge of innovation in treating mood disorders. That makes it an exciting, if quite risky, investment. External developments could have big implications The second catalyst is a bit different in nature. Compass isn't the only biotech working on developing psychedelic medicines. Lykos Therapeutics is a for-profit public benefit corporation (PBC) that aims ...